mFluiDx is developing a point-of-care molecular test - the “SIMPLE CHIP” that achieves cost parity with rapid antigen tests while delivering PCR equivalent results with multiple pathogens tested at the same time. Successful deployment will allow rapid, decentralized, immediate screening on-site (small clinics, pharmacies, etc.).
GATES FOUNDATION-FUNDED TECHNOLOGY
UC BERKELEY SPIN-OUT STARTUP
note: due to IP confidentiality, schematic is not the newest prototype in development.
bacteria/virus/DNA/RNA molecular testing
Low cost: microfluidics technology enables an extremely low-cost consumable cartridge and reader instrument.
Multi-target testing: a single disposable cartridge can detect multiple infectious agents (viral and or bacterial) from a patient in one single test.
Fast: 7~15min turnaround
High sensitivity/specificity: we are using isothermal amplification that has equivalent performance to PCR.
Automated: sample-to-answer including sample prep is fully automated.
Techcrunch Battlefield Finalist
mFluiDx selected as one of the top 20 startups to pitch at Techcrunch Battlefield, from a pool of 900 startups globally. Founder and CEO- Charlie Yeh (UCSF/UC Berkeley Joint PhD in Bioengineering)